glp 1 gastric issues a) GLP-1R mediated decrease in the production rate of intestinally GLP-1 and Gut Health: Addressing

Retatrutide is a next-generation weight loss injection developed by Eli Lilly (same manufacturer as Mounjaro), designed to target three separate hormone receptors in the body: the GLP-1 receptor, the GIP receptor, and the glucagon receptor

[8] [9] Dulaglutide (Trulicity) is FDA-approved only for type 2 diabetes management, not for weight loss

Visualizations Notes: This visualization displays fee-for-service (FFS) retail pharmaceutical costs (billed on a pharmacy claim) paid by an insurance plan only

Leveraging the University of California Health Data Warehouse enabled a realworld analysis of 6,871 patients with primary colon cancer and rigorous adjustment strategies to probe whether GLP1 RA exposure relates to fiveyear mortality. At the end of the study, researchers found that participants with colon cancer taking GLP-1 medications had a 15.5% mortality risk within 5 years, compared to 37.1% in participants not taking the drugs